This segment focuses on the research, development, and clinical trials of AV-101, a dry powder inhaled formulation of imatinib, for the treatment of Pulmonary Arterial Hypertension (PAH). The company utilizes advanced inhalation technology to deliver the drug directly to the lungs, aiming to improve patient outcomes by targeting the underlying mechanisms of PAH. Research and development activities include Phase 2b/3 clinical trials (IMPAHCT study) to evaluate the efficacy and safety of AV-101. The segment's market positioning is centered on addressing a significant unmet medical need in the rare disease space, with a focus on providing a novel inhaled therapeutic option. Future opportunities include potential expansion into other cardiopulmonary diseases and strategic partnerships to accelerate drug development and commercialization. Regulatory and clinical aspects involve rigorous clinical trials and seeking FDA approval. The patient impact is significant, as PAH is a life-threatening condition, and AV-101 aims to improve the quality of life and survival rates for affected individuals.